GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Steminent Biotherapeutics 7729.TWO · TWD

N/A · Taipei Exchange · 🇹🇼 Taiwan

Compare

201.00

+7.20%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Steminent Biotherapeutics

Its shares trade on Taipei Exchange under the ticker 7729.TWO. It has been listed since 11 March 2024. In the fiscal year to 31 December 2023, it reported revenue of TWD 941,000 and a net loss of TWD 129.2m. At that date it held total assets of TWD 593.9m and shareholders' equity of TWD 493.0m.

Steminent Biotherapeutics Inc is a TW-based company operating in industry. The company is headquartered in Taipei City, Taipei. The company went IPO on 2024-03-11. Steminent Biotherapeutics Inc is a Taiwan-based trading company mainly engaged in the research and development of new stem cell drugs and the development of allogeneic mesenchymal stem cell technology platforms. The firm's main product is the new stem cell drug product Stemchymal. The new stem cell drug product Stemchymal is used to treat spinocerebellar ataxia, Huntington's disease, acute ischemic stroke, acute inflammatory indications and other diseases.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
11 Mar 2024

Leadership

Pay as last reported

  • Mr. Zhanyu LiDirector
  • Hongsheng LinDirector

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Stemchymal treats spinocerebellar ataxia and Huntington's disease with innovative stem cell technology.
  • Taipei City headquarters supports research and development in Taiwan's biotech sector.
  • Allogeneic mesenchymal stem cell technology platform enables scalable drug development.

Weaknesses

  • Limited product portfolio focuses solely on stem cell drugs without diversification.
  • IPO on 11 March 2024 indicates recent market entry with unproven commercial success.
  • Taiwan-based operations face potential geopolitical challenges in global markets.

Opportunities

  • Expanding into acute ischemic stroke treatment using Stemchymal technology.
  • Growing demand for stem cell therapies in the global health care market.
  • Partnerships with international research institutions to enhance technology platforms.

Threats

  • Regulatory hurdles in the United States for stem cell drug approvals.
  • Competition from established biotech firms in the health care sector.
  • Geopolitical tensions affecting Taiwan's access to international markets.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.